Created on:
July 6, 2023

PaxMedica Grants Exclusive Pharmacy Distribution Rights

Exclusive pharmacy distribution agreement for PaxMedica’s lead pipeline asset, PAX-101, granted to Vox Nova LLC

TARRYTOWN, NY and HUDSON, OH – July 6, 2023 – PaxMedica, Inc. (Nasdaq: PXMD) and Vox Nova LLC (VoxNova), a privately held corporation, today announced that they have signed an exclusive pharmacy distribution agreement for PaxMedica’s lead pipeline asset, PAX-101.

Michael Mindala, CEO of VoxNova, commented, “Through our collaboration with the experts at PaxMedica, we firmly believe that we can create a truly transformational healthcare service that continually adapts to the evolving needs of individuals with ASD and their families.  Throughthe teamwork, dedication, and shared mission of PaxMedica and VoxNova, we will strive to empower and improve the lives of ASD patients, families, caregivers and the ASD communities, and work together to foster an environment that promotes understanding, compassion, and optimal healthcare outcomes."

Howard Weisman, CEO of PaxMedica, added, “The partnership between VoxNova and PaxMedica has been designed to establish the initial infrastructure that we believe is necessary to distribute PAX-101 safely and effectively in the near future, should it gain FDA approval.  We are very impressed with the experienced team at VoxNova and their plan to provide high-touch support for individuals and their caregivers. Ensuring safe distribution has been an important part of our long-term strategic plan, as PaxMedica is the only public company that is exclusively focused on treating the core symptoms of autism.”